Our History: Bridging Bio-Innovation and Vascular Stewardship
DECALCIFIL Innovations was founded on a singular, disruptive premise: Pathological ectopic calcification should not be an irreversible systemic condition.
What began as a rigorous scientific pursuit in Cluj-Napoca, Romania—a renowned European hub for technological and medical advancement—has evolved into a globally protected transdermal platform targeting pathological calcium burden without mechanical or invasive intervention.
Key Milestones in Our Journey
1. The Genesis & Fundamental Discovery
For decades, targeted decalcification posed a critical physiological paradox: how to solubilize pathological calcium deposits in soft tissues and vascular beds without compromising structural bone mineral density or destabilizing systemic ion homeostasis.
Through extensive research into metabolic chelation dynamics, our founder engineered the DECALCIFIL matrix—a proprietary transdermal delivery formulation designed to rapidly permeate the skin barrier and deliver active citrate ions directly to ectopic calcification sites.
2. Analytical & Human In Vivo Validation
To move beyond theoretical models, the technology underwent rigorous empirical testing. Utilizing Gas Chromatography-Mass Spectrometry (GC-MS), our team validated an unprecedented bio-permeation rate:
Ultra-Fast Kinetics: A +37.5% increase in systemic citrate response within 10 minutes of transdermal application—achieved entirely without physical acceleration devices or micro-needling.
Tissue Stewardship: Clinical observations confirmed high target specificity toward labile, ectopic calcium deposits while preserving structural bone matrix and maintaining complete hemodynamic safety.
3. Global Intellectual Property Framework
Recognizing the transformative commercial potential across cardiovascular, orthopedic, and systemic calcification disorders, DECALCIFIL Innovations secured global IP protection under the WIPO Patent Cooperation Treaty (PCT) Priority Date: March 2025 (OSIM Deposit).
This robust IP foundation guarantees strategic exclusivity and opens clear pathways for regional partnerships, M&A, and worldwide licensing.
Looking Forward: Strategic Commercialization
Today, DECALCIFIL stands at the threshold of global scale. Operated as an agile IP spin-off, our mission is to partner with leading pharmaceutical manufacturers, biotech venture funds, and IP licensing brokers to accelerate market entry, clinical expansion, and patient access worldwide.
"We did not merely invent a formulation; we unlocked a rapid, non-invasive mechanism to restore tissue elasticity and vascular balance."
— Filo, Founder & Principal Inventor